Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bjps.2013.04.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging.
Eur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland.
Purpose: Long axial field-of-view (LAFOV) positron emission tomography/computed tomography (PET/CT) scanners enable high sensitivity and wide anatomical coverage. Therefore, they seem ideal to perform post-selective internal radiation therapy (SIRT) Y scans, which are needed, to confirm that the dose is delivered to the tumors and that healthy organs are spared. However, it is unclear to what extent the use of LAFOV PET is feasible and which dosimetry approaches results in accurate measurements.
View Article and Find Full Text PDFThe Preliminary Results of a Modified Von Langenbeck Cleft Palate Repair With Tension-free Mucoperiosteal Flap Near Nasal Cavity Without Relaxation Incision.
J Craniofac Surg
December 2024
Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, & People's Hospital of Morin Dawa Daur Autonomous Banner, Inner Mongolia Autonomous Region, People's Republic of China.
To explore the application of modified Von Langenbeck cleft palate repair with tension-free mucoperiosteal flap near the nasal cavity and without relaxation incision, and the cleft palate defect was repaired by covering both sides of the edge of the in situ mucoperiosteal flap. This treatment method provides a good aesthetic restoration effect. Modified Von Langenbeck cleft palate repair with mucoperiosteal flap near the nasal cavity without tension and relaxation incision was used to repair the cleft palate.
View Article and Find Full Text PDFComputed Tomography Coronary Angiography Is Feasible and Reliable for Proximal Coronary Segment Interpretation in Patients with Elevated Body Mass Index.
J Cardiovasc Dev Dis
December 2024
Faculty of Medicine, Monash University, Wellington Rd, Melbourne 3800, Australia.
Computed tomography coronary angiography (CTCA) is under-utilised in detecting coronary artery disease (CAD) in obese patients due to concerns about non-evaluable testing. We hypothesise that these concerns are predominantly related to smaller and branch coronary vessels, and CTCA remains adequate for proximal segment stenosis interpretation, which has significant clinical implications. This retrospective cohort study, on consecutive patients referred for CTCA for suspected CAD, grouped patients by body mass index.
View Article and Find Full Text PDFEvaluation of the Efficacy and Accuracy of Super-Flexible Three-Dimensional Heart Models of Congenital Heart Disease Made via Stereolithography Printing and Vacuum Casting: A Multicenter Clinical Trial.
J Cardiovasc Dev Dis
December 2024
Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Suita 564-8565, Japan.
Three-dimensional (3D) printing is an advanced technology for accurately understanding anatomy and supporting the successful surgical management of complex congenital heart disease (CHD). We aimed to evaluate whether our super-flexible 3D heart models could facilitate preoperative decision-making and surgical simulation for complex CHD. The super-flexible heart models were fabricated by stereolithography 3D printing of the internal and external contours of the heart from cardiac computed tomography (CT) data, followed by vacuum casting with a polyurethane material similar in elasticity to a child's heart.
View Article and Find Full Text PDFIndependent Validation of a HER2-low Focused IHC Scoring System for Enhanced Pathologist Precision and Consistency.
Mod Pathol
December 2024
Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
For two decades the ASCO CAP HER2 testing criteria have included 0 and 1+ scores, but this distinction was inconsequential. Now, based on the DESTINY Breast-04 Trial (DB-04) results, for patients with metastatic breast cancer it underpins eligibility for T-DXd treatment. Discerning 0 from 1+ IHC staining is challenging, as HER2 low is not a biologically distinct cancer subset, there are no reference standards or controls and second-tier tests do not apply.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!